212 related articles for article (PubMed ID: 26867771)
21. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
22. BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk.
Auranen A; Spurdle AB; Chen X; Lipscombe J; Purdie DM; Hopper JL; Green A; Healey CS; Redman K; Dunning AM; Pharoah PD; Easton DF; Ponder BA; Chenevix-Trench G; Novik KL
Int J Cancer; 2003 Jan; 103(3):427-30. PubMed ID: 12471628
[TBL] [Abstract][Full Text] [Related]
23. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
[TBL] [Abstract][Full Text] [Related]
25. Parkin gene alterations in ovarian carcinoma from northern Indian population.
Mehdi SJ; Ali A; Rizvi MM
Pathol Oncol Res; 2011 Sep; 17(3):579-86. PubMed ID: 21221875
[TBL] [Abstract][Full Text] [Related]
26. The associations between MDM4 gene polymorphisms and cancer risk.
Wang MJ; Luo YJ; Shi ZY; Xu XL; Yao GL; Liu RP; Zhao H
Oncotarget; 2016 Aug; 7(34):55611-55623. PubMed ID: 27742919
[TBL] [Abstract][Full Text] [Related]
27. Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.
Grandi G; Perrone AM; Chiossi G; Friso S; Toss A; Sammarini M; Facchinetti F; Botticelli L; Palma F; De Iaco P
Gynecol Oncol; 2019 Jul; 154(1):163-168. PubMed ID: 31104904
[TBL] [Abstract][Full Text] [Related]
28. Impact of
Helwa R; Gansmo LB; Bjørnslett M; Halle MK; Werner HMJ; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
Biomarkers; 2021 Jun; 26(4):302-308. PubMed ID: 33645339
[TBL] [Abstract][Full Text] [Related]
29. An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.
Desai P; Wallace R; Anderson ML; Howard BV; Ray RM; Wu C; Safford M; Martin LW; Rohan T; Manson JE; Simon MS
Gynecol Oncol; 2018 Mar; 148(3):540-546. PubMed ID: 29422345
[TBL] [Abstract][Full Text] [Related]
30. MDM4 genetic variants and risk of gastric cancer in an Eastern Chinese population.
Wang MY; Jia M; He J; Zhou F; Qiu LX; Sun MH; Yang YJ; Wang JC; Jin L; Wang YN; Wei QY
Oncotarget; 2017 Mar; 8(12):19547-19555. PubMed ID: 28099948
[TBL] [Abstract][Full Text] [Related]
31. MDM4: What do we know about the association between its polymorphisms and cancer?
Almeida GM; Castilho AC; Adamoski D; Braun-Prado K
Med Oncol; 2022 Dec; 40(1):61. PubMed ID: 36566308
[TBL] [Abstract][Full Text] [Related]
32. The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.
Heubner M; Wimberger P; Riemann K; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
Oncol Res; 2010; 18(7):343-7. PubMed ID: 20377136
[TBL] [Abstract][Full Text] [Related]
33. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
Berchuck A; Schildkraut JM; Wenham RM; Calingaert B; Ali S; Henriott A; Halabi S; Rodriguez GC; Gertig D; Purdie DM; Kelemen L; Spurdle AB; Marks J; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2141-7. PubMed ID: 15598772
[TBL] [Abstract][Full Text] [Related]
34. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
[TBL] [Abstract][Full Text] [Related]
35. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
BMC Cancer; 2017 Feb; 17(1):97. PubMed ID: 28158999
[TBL] [Abstract][Full Text] [Related]
36. Low-dose aspirin use and the risk of ovarian cancer in Denmark.
Baandrup L; Kjaer SK; Olsen JH; Dehlendorff C; Friis S
Ann Oncol; 2015 Apr; 26(4):787-792. PubMed ID: 25538177
[TBL] [Abstract][Full Text] [Related]
37. Lack of Associations of the MDM4 rs4245739 Polymorphism with Risk of Thyroid Cancer among Iranian-Azeri Patients: a Case-Control Study.
Mohammad Khanlou Z; Pouladi N; Hosseinpour Feizi M; Pedram N
Asian Pac J Cancer Prev; 2017 Apr; 18(4):1133-1138. PubMed ID: 28547953
[TBL] [Abstract][Full Text] [Related]
38. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
39. A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility.
Zhai Y; Dai Z; He H; Gao F; Yang L; Dong Y; Lu J
Oncotarget; 2016 Nov; 7(45):73935-73944. PubMed ID: 27738340
[TBL] [Abstract][Full Text] [Related]
40. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Weiderpass E; Persson IR
J Natl Cancer Inst; 2002 Apr; 94(7):497-504. PubMed ID: 11929950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
